Sotyktu (deucravacitinib tablets) — Medica

Initial criteria

• age ≥ 18 years
• Patient meets ONE of the following (a or b): a) Patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant; OR b) According to the prescriber, the patient has a contraindication to methotrexate
• Medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has been established on therapy for at least 3 months
• Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating the requested drug) in at least one of the following: estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis
• Compared with baseline, patient experienced an improvement in at least one symptom, such as decreased pain, itching, and/or burning

Approval duration

Initial: 3 months; Reauthorization: 1 year